Encoded Therapeutics
7
3
5
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
14.3%
1 terminated/withdrawn out of 7 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Role: lead
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation
Role: collaborator
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
Role: lead
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
Role: lead
Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies
Role: lead
GABA Biomarkers in Dravet Syndrome
Role: collaborator
Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome
Role: collaborator
All 7 trials loaded